Pharmaceuticals
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, issued its 2022 semi-annual report today. As disclosed in...
2022-08-25 00:46
2345
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results. Business Highlights * CT053: comple...
2022-08-24 20:50
2619
Jacobio Pharma Announces 2022 Interim Results
Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million. Global development of KRAS G12C inhibitor and other clinical stage drug candidates accelerated. Development started in new pre-clinical stage drug candidates, such as iADC (immunostimulatory antibody-dr...
2022-08-24 00:32
2872
I-Mab Announces Share Purchase Plans by the Company and the Senior Management
GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases...
2022-08-23 21:13
3126
AVELOS THERAPEUTICS ANNOUNCES $8 MILLON SERIES A FUNDING ROUND
Seoul-Based Biotechnology Company to Use Financing for Expanding Oncology Drug Discovery and Development SEOUL, South Korea, Aug. 22, 2022 /PRNewswire/ -- Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement ...
2022-08-22 20:00
1760
Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer
NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leading global R&D biotechnology company, today announced the appointment ofSteven Knapp, PharmD., as Chief Regulatory & Quality Officer. In this position, he is responsible for the strategic leadership...
2022-08-22 13:00
1618
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
- Major updates will focus on global clinical development of core assets, upcoming milestones and financial results - The Company will update on potential implementation of a comprehensive share purchase program by the Company and current shareholders - Conference Calls Scheduled at 7:00 a.m....
2022-08-19 21:00
2014
World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA
SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 19, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today that the Center for Drug ...
2022-08-19 18:41
1844
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial ofEnsifentrine for the maintenance treatment of chronic obstructive pulmonary ...
2022-08-19 11:24
1343
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Compa...
2022-08-18 23:46
1295
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17
* Nuvaxovid™ is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New...
2022-08-18 21:06
2058
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a case report, titled "Long Term Complete Response of Advanced H...
2022-08-18 20:50
1695
Standigm names Carl Foster chief business officer to expand strategic partnerships for AI drug discovery
Veteran biotech and pharmaceutical executive will help company increase its
growth and international impact
SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- Standigm Inc.
2022-08-18 20:30
1608
GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has approved the clinical trial application for GFH312 in a randomized, double-blind...
2022-08-18 19:00
1589
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
* Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine * Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine GAITHERSBURG, Md., Aug. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...
2022-08-17 20:00
2944
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware
MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...
2022-08-17 01:47
4115
STANDIGM WINS GOLD AND BRONZE STEVIE® AWARDS IN 2022 INTERNATIONAL BUSINESS AWARDS®
Winners to Be Celebrated During Event in London on 15 October
SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- Standigm
2022-08-16 20:30
2527
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022
JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022. Mr. Gang Lai, Chairman and ...
2022-08-16 20:00
2656
JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.
SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcomin...
2022-08-12 10:13
1635
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient inAustralia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring...
2022-08-10 20:00
1521
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2931
